Triclofos
Triclofos is a prodrug of trichloroethanol (similar to chloral hydrate) that is metabolized in the body to the active CNS depressant trichloroethanol, which potentiates GABA-A receptor activity to produce sedation, hypnosis, and anxiolysis. It is used as a sedative for procedural sedation in children and for insomnia, particularly as a pre-medication before EEG recordings or imaging procedures requiring pediatric sedation. Its slower onset compared to chloral hydrate and less pungent taste make it somewhat more acceptable in pediatric use.
Peso molecular
229,3800 g/mol
LogP
0,30
TPSA
66,80 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estructura 2D
Cite this structure
Embed this structure
SMILES
O=P(O)(O)OCC(Cl)(Cl)Cl
InChI
InChI=1S/C2H4Cl3O4P/c3-2(4,5)1-9-10(6,7)8/h1H2,(H2,6,7,8)
Molecular Formula
C2H4Cl3O4P
HBD / HBA
2 / 4
Enlaces Rotables
2
Átomos Pesados
10
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Triclofos is a prodrug of trichloroethanol (similar to chloral hydrate) that is metabolized in the body to the active CNS depressant trichloroethanol, which potentiates GABA-A receptor activity to produce sedation, hypnosis, and anxiolysis. It is used as a sedative for procedural sedation in children and for insomnia, particularly as a pre-medication before EEG recordings or imaging procedures requiring pediatric sedation. Its slower onset compared to chloral hydrate and less pungent taste make it somewhat more acceptable in pediatric use.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Triclofos is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201317. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5563. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="triclofos"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/triclofos/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/triclofos/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/triclofos/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="triclofos"></drugfyi-drug>